Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy Press Releases / By Kelley Nelson
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose Press Releases / By Intrommune
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy Press Releases / By Intrommune
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships Press Releases / By Intrommune
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board Press Releases / By Intrommune
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board Press Releases / By Intrommune
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards Press Releases / By Intrommune
